key: cord-0999400-pir3jhym
authors: Dellière, Sarah; Dudoignon, Emmanuel; Fodil, Sofiane; Voicu, Sebastian; Collet, Magalie; Oillic, Pierre-Antoine; Salmona, Maud; Dépret, François; Ghelfenstein-Ferreira, Théo; Plaud, Benoit; Chousterman, Benjamin; Bretagne, Stéphane; Azoulay, Elie; Mebazaa, Alexandre; Megarbane, Bruno; Alanio, Alexandre
title: Risk factors associated with Covid-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort
date: 2020-12-13
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.12.005
sha: 93ef0721feabe1fe2586dbaaacc6821ab036f7ac
doc_id: 999400
cord_uid: pir3jhym

OBJECTIVES: The main objective of this study was to determine invasive pulmonary aspergillosis (IPA) incidence in the COVID-19 patients admitted to the intensive care unit (ICU), describe the patient characteristics associated with its occurrence and evaluate the impact on prognosis. METHODS: We conducted a retrospective cohort study including all successive COVID-19 patients hospitalized in four ICUs with secondary deterioration and ≥1 respiratory sample sent to the mycology department. A strengthened IPA testing strategy including seven mycological criteria was used. Patients were classified as probable IPA according to the EORTC/MSGERC classification if immunocompromised and to the recent COVID-19-associated IPA classification otherwise. RESULTS: Probable IPA was diagnosed in 21 out of the 366 COVID-19 patients (5.7%) admitted to the ICU and the 108 patients (19.4%) who underwent respiratory sampling for deterioration. No significant differences were observed between patients with and without IPA regarding age, gender, medical history and severity on admission and during hospitalization. Treatment with azithromycin for ≥3 days was associated with the diagnosis of probable IPA (odds ratio, 3.1; 95%-confidence interval, 1.1-8.5; p=0.02). A trend was observed with high dose dexamethasone and the occurrence of IPA. Overall mortality was higher in the IPA patients (15/21, 71.4% vs. 32/87, 36.8%; p<0.01). CONCLUSION: IPA is a relatively frequent complication in severe COVID-19 patients responsible for increased mortality. Azithromycin, known to have immunomodulatory properties, may contribute to increase COVID-19 patient susceptibility to IPA.

We conducted a retrospective cohort study including all successive COVID-19 patients 37 hospitalized in four ICUs with secondary deterioration and ≥1 respiratory sample sent to the mycology 38 department. A strengthened IPA testing strategy including seven mycological criteria was used. ≥3 days was associated with the diagnosis of probable IPA (odds ratio, 3.1; 95%-confidence interval, 1.1-8.5; p=0.02). A trend was observed with high dose dexamethasone and the occurrence of IPA.

Although pulmonary invasive fungal disease is typically described in the immunocompromised host, 58 invasive pulmonary aspergillosis (IPA) has been increasingly reported in critically ill patients 59 including patients without classical risk factors of immunosuppression [1] . In acute respiratory distress Table 1) . Prescription of hydroxychloroquine (n=34) did not differ between both groups.

Administration of azithromycin for more than 3 days (cumulative dose ≥1500mg) was associated with 124 probable IPA (OR, 3.1; IC95%, 1.1-8.5; p=0.025) ( Figure S1 ). Of note, 34 patients received 125 azithromycin, which was prematurely discontinued on day 1 or day 2 in 8 patients because of QT 126 interval prolongation. Administration of high-dose corticosteroids was not significantly associated 127 with IPA (11.5 vs. 28.6%; p=0.08), although the cumulative dose ≥100 mg tended to be higher among 128 IPA patients (OR, 3.7; IC95%, 1.0-9.7). Details for the incidence of IPA among patients who received 129 azithromycin and/or corticosteroids is available in Table S3 

Epidemiology of 192 invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study

A national strategy to 195 diagnose COVID-19 associated invasive fungal disease in the ICU

Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a 199 retrospective cohort study

Trends in invasive fungal infections, with 202 emphasis on invasive aspergillosis

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the 206

European Organization for Research and Treatment of Cancer and the Mycoses Study Group 207 Education and Research Consortium

Review 210 of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case 211 definition: an expert opinion

Glucocorticoids and invasive fungal infections

New 216 therapeutic strategies for invasive aspergillosis in the era of azole resistance: how should the 217 prevalence of azole resistance be defined?: Table 1

Aspergillus fumigatus DNA Is Quantitatively Correlated to Galactomannan in Serum

Azithromycin for severe COVID-19

CT lung lesions as 240 predictors of early death or ICU admission in COVID-19 patients